ExanguinationSTABLE-EMSNCT07646964
Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World Conditions
An observational study of Exanguination and Trauma Coagulopathy, run by Medical University of Graz at 1 site in Austria.
Trial summary
Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months. These conditions may affect the stability and quality of medications and blood products carried for emergency treatment. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Exanguination, Trauma Coagulopathy
- How many people
- 2 participants
- Where
- 1 siteAustria
- Study dates
- 1 Jul 2026to 30 Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: no study population
Who may be able to join
- Fibryga samples stored in the participating ground-based EMS ambulance.
- Octaplas LG AB samples stored in the participating ground-based EMS ambulance.
- Samples available for laboratory analysis at the predefined study time points.
- Samples exposed to routine operational storage conditions during the study period.
Who cannot join
- Samples with damaged packaging.
- Samples with incomplete storage documentation.
- Samples accidentally removed from the designated storage system during the observation period.
- Samples unavailable for laboratory analysis.
- Samples exposed to conditions not representative of routine EMS operation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Austria1 site, 1 recruiting
- Recruiting
Medical University of Graz
Graz, 8010
Gabriel Honnef, MD, PhD, 031638581283, gabriel.honnef@medunigraz.at
About this study
Official title: Stability of Human Fibrinogen (Fibryga) and Lyophilized Human Plasma (Octaplas LG AB) Under Real-World Prehospital Emergency Medical Service Storage Conditions: A Prospective Observational Study
Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months. These conditions may affect the stability and quality of medications and blood products carried for emergency treatment.
This observational study aims to evaluate the stability of human fibrinogen concentrates and human plasma proteins (Octaplas) when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. Drug samples will be analyzed monthly over a four-month period and compared with reference samples stored under recommended conditions. In addition, temperature inside the storage containers and the vehicle will be continuously monitored.
The study will assess whether prolonged exposure to real-world prehospital storage conditions affects product stability and whether any changes are associated with environmental factors. The findings may help determine whether current storage practices in EMS vehicles are adequate for maintaining the quality of these blood coagulation products.
Read the detailed description
Emergency medical service (EMS) medications and blood products are routinely exposed to varying environmental conditions during storage and transport. Seasonal temperature fluctuations, prolonged vehicle operation, and environmental influences may result in deviations from manufacturer-recommended storage conditions. While several studies have demonstrated the stability of commonly used emergency medications under real-world prehospital conditions, limited evidence is available regarding the stability of blood coagulation products stored in EMS vehicles.
Human fibrinogen concentrates and lyophilized human plasma (Octaplas LG AB) are increasingly available in prehospital emergency care for the early management of severe hemorrhage and trauma. Both products are subject to specific storage requirements defined by the manufacturer. Although these products are intended to be stored under controlled conditions, maintaining recommended storage environments continuously in operational EMS vehicles may be challenging, particularly during periods of elevated ambient temperatures. Data regarding the impact of such environmental exposure on product stability in the prehospital setting remain scarce.
The objective of this prospective observational longitudinal study is to evaluate the stability of fibrinogen concentrates and Octaplas LG AB when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. The study will be conducted during the summer months from July through September 2026, representing the period with the highest expected thermal stress on medical products stored in emergency vehicles.
At study initiation, reference samples of both products will be retained under manufacturer-recommended storage conditions. Additional study samples will be placed in the ambulance medication storage system and exposed to routine operational conditions throughout the observation period. Laboratory analyses will be performed at predefined monthly intervals to assess potential changes in product stability over time. All analyses will be conducted at the Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, using validated laboratory methods appropriate for each product. Product-specific stability parameters will be compared with baseline and reference samples stored according to manufacturer recommendations.
Environmental conditions will be continuously monitored throughout the study period. Temperature sensors will be installed both within the medication storage containers and inside the ambulance vehicle. Measurements will be recorded automatically at 10-minute intervals over the entire observation period. These data will be used to characterize environmental exposure profiles and to quantify the frequency, magnitude, and duration of deviations from recommended storage conditions.
The primary objective is to determine whether storage under real-world prehospital operating conditions results in measurable changes in the stability of fibrinogen concentrates and Octaplas LG AB over a three-month observation period. Secondary objectives are to characterize temperature conditions within EMS medication storage systems, assess compliance with manufacturer-recommended storage conditions, quantify environmental excursions outside recommended storage ranges, evaluate potential associations between environmental exposure and laboratory measures of product stability, and describe seasonal storage conditions encountered in a ground-based EMS system.
No patients will be enrolled, and no clinical interventions will be performed as part of this study. The investigation is limited to pharmaceutical product samples and environmental monitoring within an operational EMS vehicle. Consequently, no patient-related outcomes, safety endpoints, adverse events, or clinical efficacy outcomes will be assessed.
Descriptive statistics will be used to summarize environmental and laboratory data. Continuous variables will be reported as means with standard deviations or medians with interquartile ranges, as appropriate. Longitudinal changes in laboratory stability parameters will be assessed across repeated measurements obtained during the observation period. Associations between environmental variables, including temperature and laboratory indicators of product stability will be explored using correlation analyses and regression-based approaches where appropriate. Missing measurements, if encountered, will not be imputed and will be reported transparently.
The results of this study are expected to provide evidence regarding the suitability of current EMS storage practices for blood coagulation products under routine operating conditions. The findings may contribute to future recommendations for the storage, transport, and quality assurance of coagulation products used in prehospital emergency medicine.
- Conditions
- Exanguination, Trauma Coagulopathy
- Keywords
- Prehospital Care, Drug Storage, Temperature Monitoring, Fibrinogen Concentrate, Lyophilized Plasma, Coagulation Products
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Fibrinogen conentrate | Human fibrinogen concentrate samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period. | |
| Octaplas LG AB | Lyophilized human plasma samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Stability of fibrinogen concentrates and Octaplas LG AB During Storage Under Real-World EMS Conditions
Change in predefined laboratory stability parameters of fibrinogen concentrates and Octaplas LG AB after storage under routine operating conditions in a ground-based emergency medical service ambulance compared with baseline reference samples stored according to manufacturer recommendations.
Measured: Baseline to 3 months
Secondary outcomes (3)
Frequency of Temperature Excursions Outside Recommended Storage Conditions
Number and duration of temperature measurements exceeding manufacturer-recommended storage limits for Fibryga and Octaplas LG AB during the observation period.
Measured: Continuously monitored from baseline to 3 months
Maximum and Minimum Storage Temperatures
Highest and lowest temperatures recorded within medication storage compartments and inside the ambulance vehicle during the study period.
Measured: Baseline to 3 months
Compliance With Manufacturer-Recommended Storage Conditions
Percentage of recorded measurements within the recommended storage conditions specified by the manufacturers of Fibryga and Octaplas LG AB.
Measured: Continuously monitored from baseline to 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2026
- Study start1 Jul 2026
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for ExanguinationStudies of the same condition, open and under way.
- More trials run by Medical University of GrazThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of Graz
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07646964
- Sponsor's protocol ID
- MUG-STABLEEMS-2026-01
- Acronym
- STABLE-EMS
- Status last verified
- Jun 2026
- First submitted
- 9 Jun 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Pietsch U, Moeckel J, Koppenberg J, Josi D, Jungwirth A, Hautz WE, Wenzel V, Strecke S, Albrecht R. Stability of Drugs Stored in Helicopters for Use by Emergency Medical Services: A Prospective Observational Study. Ann Emerg Med. 2022 Oct;80(4):364-370. doi: 10.1016/j.annemergmed.2022.05.038. Epub 2022 Aug 1.
PubMed 35927113Helm M, Castner T, Lampl L. Environmental temperature stress on drugs in prehospital emergency medical service. Acta Anaesthesiol Scand. 2003 Apr;47(4):425-9. doi: 10.1034/j.1399-6576.2003.00062.x.
PubMed 12694141
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Stability of Human Fibrinogen (Fibryga) and Lyophilized Human Plasma (Octaplas LG AB) Under Real-World Prehospital Emergency Medical Service Storage Conditions: A Prospective Observational Study
- ClinicalTrials.gov ID
- NCT07646964
- Acronym / sponsor ID
- STABLE-EMS / MUG-STABLEEMS-2026-01
- Conditions
- Exanguination, Trauma Coagulopathy
- Keywords
- Prehospital Care, Drug Storage, Temperature Monitoring, Fibrinogen Concentrate, Lyophilized Plasma, Coagulation Products
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2 participants (estimated)
- Lead sponsor
- Medical University of GrazUniversity, hospital or other
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Nov 2026 (estimated)
- First posted
- 15 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months. These conditions may affect the stability and quality of medications and blood products carried for emergency treatment.
This observational study aims to evaluate the stability of human fibrinogen concentrates and human plasma proteins (Octaplas) when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. Drug samples will be analyzed monthly over a four-month period and compared with reference samples stored under recommended conditions. In addition, temperature inside the storage containers and the vehicle will be continuously monitored.
The study will assess whether prolonged exposure to real-world prehospital storage conditions affects product stability and whether any changes are associated with environmental factors. The findings may help determine whether current storage practices in EMS vehicles are adequate for maintaining the quality of these blood coagulation products.
Detailed description
Emergency medical service (EMS) medications and blood products are routinely exposed to varying environmental conditions during storage and transport. Seasonal temperature fluctuations, prolonged vehicle operation, and environmental influences may result in deviations from manufacturer-recommended storage conditions. While several studies have demonstrated the stability of commonly used emergency medications under real-world prehospital conditions, limited evidence is available regarding the stability of blood coagulation products stored in EMS vehicles.
Human fibrinogen concentrates and lyophilized human plasma (Octaplas LG AB) are increasingly available in prehospital emergency care for the early management of severe hemorrhage and trauma. Both products are subject to specific storage requirements defined by the manufacturer. Although these products are intended to be stored under controlled conditions, maintaining recommended storage environments continuously in operational EMS vehicles may be challenging, particularly during periods of elevated ambient temperatures. Data regarding the impact of such environmental exposure on product stability in the prehospital setting remain scarce.
The objective of this prospective observational longitudinal study is to evaluate the stability of fibrinogen concentrates and Octaplas LG AB when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. The study will be conducted during the summer months from July through September 2026, representing the period with the highest expected thermal stress on medical products stored in emergency vehicles.
At study initiation, reference samples of both products will be retained under manufacturer-recommended storage conditions. Additional study samples will be placed in the ambulance medication storage system and exposed to routine operational conditions throughout the observation period. Laboratory analyses will be performed at predefined monthly intervals to assess potential changes in product stability over time. All analyses will be conducted at the Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, using validated laboratory methods appropriate for each product. Product-specific stability parameters will be compared with baseline and reference samples stored according to manufacturer recommendations.
Environmental conditions will be continuously monitored throughout the study period. Temperature sensors will be installed both within the medication storage containers and inside the ambulance vehicle. Measurements will be recorded automatically at 10-minute intervals over the entire observation period. These data will be used to characterize environmental exposure profiles and to quantify the frequency, magnitude, and duration of deviations from recommended storage conditions.
The primary objective is to determine whether storage under real-world prehospital operating conditions results in measurable changes in the stability of fibrinogen concentrates and Octaplas LG AB over a three-month observation period. Secondary objectives are to characterize temperature conditions within EMS medication storage systems, assess compliance with manufacturer-recommended storage conditions, quantify environmental excursions outside recommended storage ranges, evaluate potential associations between environmental exposure and laboratory measures of product stability, and describe seasonal storage conditions encountered in a ground-based EMS system.
No patients will be enrolled, and no clinical interventions will be performed as part of this study. The investigation is limited to pharmaceutical product samples and environmental monitoring within an operational EMS vehicle. Consequently, no patient-related outcomes, safety endpoints, adverse events, or clinical efficacy outcomes will be assessed.
Descriptive statistics will be used to summarize environmental and laboratory data. Continuous variables will be reported as means with standard deviations or medians with interquartile ranges, as appropriate. Longitudinal changes in laboratory stability parameters will be assessed across repeated measurements obtained during the observation period. Associations between environmental variables, including temperature and laboratory indicators of product stability will be explored using correlation analyses and regression-based approaches where appropriate. Missing measurements, if encountered, will not be imputed and will be reported transparently.
The results of this study are expected to provide evidence regarding the suitability of current EMS storage practices for blood coagulation products under routine operating conditions. The findings may contribute to future recommendations for the storage, transport, and quality assurance of coagulation products used in prehospital emergency medicine.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fibrinogen conentrate | – | –Human fibrinogen concentrate samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period. |
| Octaplas LG AB | – | –Lyophilized human plasma samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period. |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- no study population
Key inclusion criteria (4 listed)
- Fibryga samples stored in the participating ground-based EMS ambulance.
- Octaplas LG AB samples stored in the participating ground-based EMS ambulance.
- Samples available for laboratory analysis at the predefined study time points.
- Samples exposed to routine operational storage conditions during the study period.
Key exclusion criteria (5 listed)
- Samples with damaged packaging.
- Samples with incomplete storage documentation.
- Samples accidentally removed from the designated storage system during the observation period.
- Samples unavailable for laboratory analysis.
- Samples exposed to conditions not representative of routine EMS operation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Stability of fibrinogen concentrates and Octaplas LG AB During Storage Under Real-World EMS Conditions
Time frame: Baseline to 3 months
Change in predefined laboratory stability parameters of fibrinogen concentrates and Octaplas LG AB after storage under routine operating conditions in a ground-based emergency medical service ambulance compared with baseline reference samples stored according to manufacturer recommendations.
3 secondary outcomes
Frequency of Temperature Excursions Outside Recommended Storage Conditions
Time frame: Continuously monitored from baseline to 3 months
Maximum and Minimum Storage Temperatures
Time frame: Baseline to 3 months
Compliance With Manufacturer-Recommended Storage Conditions
Time frame: Continuously monitored from baseline to 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Background: PubMed 35927113Pietsch U, Moeckel J, Koppenberg J, Josi D, Jungwirth A, Hautz WE, Wenzel V, Strecke S, Albrecht R. Stability of Drugs Stored in Helicopters for Use by Emergency Medical Services: A Prospective Observational Study. Ann Emerg Med. 2022 Oct;80(4):364-370. doi: 10.1016/j.annemergmed.2022.05.038. Epub 2022 Aug 1.
- Background: PubMed 12694141Helm M, Castner T, Lampl L. Environmental temperature stress on drugs in prehospital emergency medical service. Acta Anaesthesiol Scand. 2003 Apr;47(4):425-9. doi: 10.1034/j.1399-6576.2003.00062.x.
Related trials for Exanguination
Not yet recruitingObservational study
Abdominal Aortic Junction Tourniquet (AAJT-S) for Non-compressible Torso Haemorrhage in the Prehospital and Emergency Room Setting
Exanguination, Polytrauma
RecruitingObservational study
Abdominal Aortic Junction Tourniquet (AAJT-S) for Non-compressible Torso Haemorrhage
Exanguination, NCTH
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Exanguination and Trauma Coagulopathy, run by Medical University of Graz at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maximilian Niederer, MD (0316385081237, maximilian.niederer@medunigraz.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stability of fibrinogen concentrates and Octaplas LG AB During Storage Under Real-World EMS Conditions (time frame: Baseline to 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07646964, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.